"Chemoradiotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatment that combines chemotherapy with radiotherapy.
Descriptor ID |
D059248
|
MeSH Number(s) |
E02.186.079 E02.319.164 E02.815.160
|
Concept/Terms |
Chemoradiotherapy- Chemoradiotherapy
- Chemoradiotherapies
- Radiochemotherapy
- Radiochemotherapies
Concurrent Chemoradiotherapy- Concurrent Chemoradiotherapy
- Chemoradiotherapies, Concurrent
- Chemoradiotherapy, Concurrent
- Concurrent Chemoradiotherapies
- Synchronous Chemoradiotherapy
- Chemoradiotherapies, Synchronous
- Chemoradiotherapy, Synchronous
- Synchronous Chemoradiotherapies
- Concurrent Radiochemotherapy
- Concurrent Radiochemotherapies
- Radiochemotherapies, Concurrent
- Radiochemotherapy, Concurrent
- Concomitant Chemoradiotherapy
- Chemoradiotherapies, Concomitant
- Chemoradiotherapy, Concomitant
- Concomitant Chemoradiotherapies
- Concomitant Radiochemotherapy
- Concomitant Radiochemotherapies
- Radiochemotherapies, Concomitant
- Radiochemotherapy, Concomitant
|
Below are MeSH descriptors whose meaning is more general than "Chemoradiotherapy".
Below are MeSH descriptors whose meaning is more specific than "Chemoradiotherapy".
This graph shows the total number of publications written about "Chemoradiotherapy" by people in this website by year, and whether "Chemoradiotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 0 | 1 | 1 |
2011 | 6 | 4 | 10 |
2012 | 5 | 6 | 11 |
2013 | 13 | 5 | 18 |
2014 | 7 | 3 | 10 |
2015 | 8 | 5 | 13 |
2016 | 8 | 9 | 17 |
2017 | 6 | 14 | 20 |
2018 | 5 | 10 | 15 |
2019 | 5 | 5 | 10 |
2020 | 9 | 4 | 13 |
2021 | 3 | 10 | 13 |
2022 | 1 | 8 | 9 |
2023 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemoradiotherapy" by people in Profiles.
-
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol. 2024 Feb 10; 42(5):500-506.
-
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. J Thorac Oncol. 2024 02; 19(2):285-296.
-
A nationwide analysis of salvage surgery for laryngeal cancer in the elderly. Head Neck. 2023 11; 45(11):2915-2924.
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 Jul 27; 389(4):322-334.
-
MRI assessment of rectal cancer response to neoadjuvant therapy: a multireader study. Eur Radiol. 2023 Aug; 33(8):5761-5768.
-
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2023 02; 18(2):181-193.
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022 12; 17(12):1415-1427.
-
Letter to the Editor: "Extramural venous invasion (EMVI) revisited: a detailed analysis of various characteristics of EMVI and their role as a predictive imaging biomarker in the neoadjuvant treatment response in rectal cancer". Abdom Radiol (NY). 2022 09; 47(9):3276-3277.
-
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022 08 10; 40(23):2546-2556.
-
Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis. Head Neck. 2022 07; 44(7):1528-1544.